• Login
    View Item 
    •   Home
    • RIVM official reports
    • RIVM official reports
    • View Item
    •   Home
    • RIVM official reports
    • RIVM official reports
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    RIVM Publications RepositoryCommunitiesTitleAuthorsIssue DateSubmit Date

    My Account

    LoginRegister

    Statistics

    Display statistics

    Poliomyelitis vaccine, inactivated. Summary of clinical documentation. Part IV

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Average rating
     
       votes
    Cast your vote
    You can rate an item by clicking the amount of stars they wish to award to this item. When enough users have cast their vote on this item, the average rating will also be shown.
    Star rating
     
    Your vote was cast
    Thank you for your feedback
    Authors
    Dirksen H
    Rumke HC
    Type
    Report
    Language
    en
    
    Metadata
    Show full item record
    Title
    Poliomyelitis vaccine, inactivated. Summary of clinical documentation. Part IV
    Translated Title
    Geinactiveerd trivalent poliomyelitisvaccin. Samenvatting van klinische documentatie. Deel IV
    Publiekssamenvatting
    Abstract niet beschikbaar
    Inactivated poliomyelitis vaccine, produced by the RIVM, has been evaluated for its immunogenic potential in humans in several countries in different vaccine compositions and in various vaccination regimes. A vaccine containing 40-8-32 DU/dose of poliovirus types, 1, 2 and 3 respectively, is considered suitable for use in humans. The vaccine is 90-100% effective after one dose given to 6-months-old infants and after 2 doses given to 2-months-old infants, when circulating antibodies are used as criterion. Although it is generally accepted that durable immunity is not only related to sero-immunity but also with immunologic memory, a third vaccination is advocated to induce longterm immunity. A vaccine of essentially the same antigenic composition and given in a two-dose regimen, has proven to be effective during an outbreak of paralytic poliomyelitis, caused by polio virus type 1. Observations of adverse events (AE) in vaccination trials, in which IPV produced by the RIVM was given in the control group and the absence of reported AE at RIVM's Medical Center Immunizations, indicate that AE of the present IPV are limited to local reactions and (undefined) irritability in a minority of recipients.
    Sponsors
    RIVM
    URI
    http://hdl.handle.net/10029/260338
    Collections
    RIVM official reports

    entitlement

     

    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.